Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging

被引:275
作者
Catalona, WJ
Southwick, PC
Slawin, KM
Partin, AW
Brawer, MK
Flanigan, RC
Patel, A
Richie, JP
Walsh, PC
Scardino, PT
Lange, PH
Gasior, GH
Loveland, KG
Bray, KR
机构
[1] Washington Univ, Sch Med, Dept Surg, Div Urol Surg, St Louis, MO 63110 USA
[2] Hybritech Inc, Dept Res & Dev, San Diego, CA USA
[3] Baylor Coll Med, Dept Urol, Houston, TX 77030 USA
[4] Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USA
[5] Univ Washington, Dept Urol, Seattle, WA 98195 USA
[6] Loyola Univ, Med Ctr, Dept Urol, Maywood, IL 60153 USA
[7] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA
[8] Brigham & Womens Hosp, Harvard Program Urol, Boston, MA 02115 USA
关键词
D O I
10.1016/S0090-4295(00)00637-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objectives. Various methods have been proposed to increase the specificity of prostate-specific antigen (PSA), including age-specific PSA reference ranges, PSA density (PSAD), and percent free PSA (%fPSA). In this multicenter study, we compared these methods for their utility in cancer detection and their ability to predict pathologic stage after radical prostatectomy in patients with clinically localized, Stage T1c cancer. Methods. Seven hundred seventy-three men (379 with prostate cancer, 394 with benign prostatic disease), 50 to 75 years old, from seven medical centers were enrolled in this prospective blinded study. All subjects had a palpably benign prostate, PSA 4.0 to 10.0 ng/mL, and a histologically confirmed diagnosis. Hybritech's Tandem PSA and free PSA assays were used. Results. %fPSA and age-specific PSA cutoffs enhanced PSA specificity for cancer detection, but %fPSA maintained significantly higher sensitivities. Age-specific PSA cutoffs missed 20% to 60% of cancers in men older than 60 years of age. %fPSA and PSAD performed equally well for detection (95% sensitivity) if cutoffs of 25% fPSA or 0.078 PSAD were used. The commonly used PSAD cutoff of 0.15 detected only 59% of cancers. %fPSA and PSAD also produced similar results for prediction of the post-radical prostatectomy pathologic stage. Patients with cancer with higher %fPSA values (greater than 15%) or lower PSAD values (0.15 or less) tended to have less aggressive disease. Conclusions. The results of this study demonstrated that cancer detection (sensitivity) is significantly higher with %fPSA than with age-specific PSA reference ranges. %fPSA and PSAD provide comparable results, suggesting that %fPSA may be used in place of PSAD for biopsy decisions and in algorithms for prediction of less aggressive tumors since the determination of %fPSA does not require ultrasound. UROLOGY 56: 255-260, 2000. (C) 2000, Elsevier Science Inc.
引用
收藏
页码:255 / 260
页数:6
相关论文
共 32 条
[1]
Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population [J].
Arcangeli, CG ;
Humphrey, PA ;
Smith, DS ;
Harmon, TJ ;
Shepherd, DL ;
Keetch, DW ;
Catalona, WJ .
UROLOGY, 1998, 51 (04) :558-564
[2]
ARCANGELI CG, 1996, J UROLOGY, V155, P415
[3]
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population [J].
Bangma, CH ;
Rietbergen, JBW ;
Kranse, R ;
Blijenberg, BG ;
Petterson, K ;
Schroder, FH .
JOURNAL OF UROLOGY, 1997, 157 (06) :2191-2196
[4]
Carter HB, 1997, UROLOGY, V49, P379
[5]
Prospective evaluation of men with stage T1c adenocarcinoma of the prostate [J].
Carter, HB ;
Sauvageot, J ;
Walsh, PC ;
Epstein, JI .
JOURNAL OF UROLOGY, 1997, 157 (06) :2206-2209
[6]
SELECTION OF OPTIMAL PROSTATE-SPECIFIC ANTIGEN CUTOFFS FOR EARLY DETECTION OF PROSTATE-CANCER - RECEIVER OPERATING CHARACTERISTIC CURVES [J].
CATALONA, WJ ;
HUDSON, MA ;
SCARDINO, PT ;
RICHIE, JP ;
AHMANN, FR ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 152 (06) :2037-2042
[7]
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547
[8]
Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination - Enhancement of specificity with free PSA measurements [J].
Catalona, WJ ;
Smith, DS ;
Ornstein, DK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1452-1455
[9]
CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214
[10]
COMPARISON OF DIGITAL RECTAL EXAMINATION AND SERUM PROSTATE-SPECIFIC ANTIGEN IN THE EARLY DETECTION OF PROSTATE-CANCER - RESULTS OF A MULTICENTER CLINICAL-TRIAL OF 6,630 MEN [J].
CATALONA, WJ ;
RICHIE, JP ;
AHMANN, FR ;
HUDSON, MA ;
SCARDINO, PT ;
FLANIGAN, RC ;
DEKERNION, JB ;
RATLIFF, TL ;
KAVOUSSI, LR ;
DALKIN, BL ;
WATERS, WB ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 151 (05) :1283-1290